Lonza has purchased Vivante GMP Solutions to give it a foothold in the viral-based manufacturing market. Lonza said the acquisition advances its strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets. Vivante, which is based in Houston, TX, produces GMP viral-based therapeutics.
Lonza
Tuesday 31 August 2010
Lonza acquires Vivante
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment